



Advancements and Applications of Artificial Intelligence in Pharmaceutical Sciences: A Comprehensive Review

Negar Mottaghi-Dastjerdi ^{1,*}, Mohammad Soltany-Rezaee-Rad ^{2,3}

¹ Department of Pharmacognosy and Pharmaceutical Biotechnology, School of Pharmacy, Iran University of Medical Sciences, Tehran, Iran

² Department of Pharmaceutical Biotechnology, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

³ Behestan Innovation Factory, Tehran, Iran

*Corresponding Author: Department of Pharmacognosy and Pharmaceutical Biotechnology, School of Pharmacy, Iran University of Medical Sciences, Tehran, Iran.
Email: mottaghi.n@iums.ac.ir

Received 2024 June 29; Revised 2024 August 4; Accepted 2024 August 11

Abstract

Artificial intelligence (AI) has revolutionized the pharmaceutical industry, improving drug discovery, development, and personalized patient care. Through machine learning (ML), deep learning, natural language processing (NLP), and robotic automation, AI has enhanced efficiency, accuracy, and innovation in the field. The purpose of this review is to shed light on the practical applications and potential of AI in various pharmaceutical fields. These fields include medicinal chemistry, pharmaceuticals, pharmacology and toxicology, clinical pharmacy, pharmaceutical biotechnology, pharmaceutical nanotechnology, pharmacognosy, and pharmaceutical management and economics. By leveraging AI technologies such as ML, deep learning, NLP, and robotic automation, this review delves into the role of AI in enhancing drug discovery, development processes, and personalized patient care. It analyzes AI's impact in specific areas such as drug synthesis planning, formulation development, toxicology predictions, pharmacy automation, and market analysis. Artificial intelligence integration into pharmaceutical sciences has significantly improved medicinal chemistry, drug discovery, and synthesis planning. In pharmaceuticals, AI has advanced personalized medicine and formulation development. In pharmacology and toxicology, AI offers predictive capabilities for drug mechanisms and toxic effects. In clinical pharmacy, AI has facilitated automation and enhanced patient care. Additionally, AI has contributed to protein engineering, gene therapy, nanocarrier design, discovery of natural product therapeutics, and pharmaceutical management and economics, including marketing research and clinical trials management. Artificial intelligence has transformed pharmaceuticals, improving efficiency, accuracy, and innovation. This review highlights AI's role in drug development and personalized care, serving as a reference for professionals. The future promises a revolutionized field with AI-driven methodologies.

Keywords: Artificial Intelligence, Biotechnology, Clinical Pharmacy, Medicinal Chemistry, Personalized Medicine, Nanotechnology, Pharmaceutical Management, Pharmacognosy, Pharmacology, Toxicology

1. Context

Artificial intelligence (AI) has revolutionized various scientific areas, including pharmaceutical sciences (1). This technology, which includes machine learning (ML), deep learning, natural language processing (NLP), and robotic automation, has transformed all fields of pharmaceutical sciences, including research and development as well as clinical practice (2).

Artificial intelligence systems use algorithms to process large datasets, identifying patterns and making predictions through training. By adjusting parameters, these models learn to minimize errors. Once trained, they analyze new data, offering insights and performing

tasks such as data analysis, pattern recognition, and predictive modeling with high accuracy and efficiency (3).

There have been numerous challenges in the pharmaceutical industry, including lengthy drug discovery processes, extensive development costs, intricate procedures for drug design, and strict therapeutic intervention requirements (4). Artificial intelligence integration into this field has given pharmaceutical professionals hope to overcome these challenges by improving efficiency, accuracy, and innovation (5). The ability of AI to process large amounts of data, extract patterns, analyze information, and make predictions positions AI as a pivotal aspect of research

and development, offering unique opportunities for innovation (6). Figure 1 and Figure 2 illustrate AI's application in pharmaceutical sciences and its historical development. The article provides a comprehensive overview of AI models and their practical applications across various fields, serving as a valuable reference for professionals integrating AI into their work.

2. Overview of Artificial Intelligence Models Utilized in Pharmaceutical Sciences

In pharmaceutical sciences, various AI models are employed for different purposes, each offering distinct capabilities and applications. Machine learning models, such as supervised learning, are fundamental in this field. Supervised learning involves training models using labeled datasets to make predictions or decisions. Techniques like regression models, support vector machines (SVM), and decision trees are commonly used. For instance, SVMs classify drug compounds based on chemical properties, aiding drug discovery. Regression models predict drug efficacy and pharmacokinetic properties, while decision trees assist in predicting patient responses and optimizing drug formulations (7).

Unsupervised learning, another crucial type of ML, focuses on uncovering patterns in unlabeled data. Clustering algorithms group similar compounds based on chemical properties, helping identify potential drug candidates. Principal component analysis (PCA) reduces data dimensionality, preserving essential information and revealing patterns that guide drug discovery (8).

Deep learning models, including Convolutional Neural Networks (CNNs) and Recurrent Neural Networks (RNNs) with long short-term memory (LSTM) networks, are pivotal. Convolutional Neural Networks excel in analyzing structured data like images, which is useful in medical imaging for disease diagnosis and drug repurposing. Recurrent Neural Networks and LSTMs process sequential data, predicting patient outcomes and identifying novel drug indications by analyzing relationships between drugs and patient characteristics (9).

Natural language processing is critical in handling unstructured text data, such as scientific literature and electronic health records (EHRs). Natural language processing extracts drug-target interactions and other crucial insights, supporting drug discovery and improving patient care. It also aids in mining medical records for adverse drug reactions (ADR), enhancing pharmacovigilance (10).

Reinforcement learning (RL) involves an agent learning decision-making by interacting with an

environment and receiving feedback. In pharmaceutical sciences, RL optimizes clinical trial designs and personalizes treatment plans. It helps in designing adaptive clinical trials, optimizing patient recruitment, and adjusting treatment protocols based on individual patient responses (11).

3. Artificial Intelligence in Medicinal Chemistry

Artificial intelligence's integration into medicinal chemistry marks a significant evolution from traditional pharmaceutical discovery methods, offering new avenues for drug design, synthesis, and optimization (12). The high costs and complexity associated with drug development, particularly due to the high attrition rates in clinical trials and the complexities of the drug discovery phase, necessitate more efficient approaches (5). Artificial intelligence provides these by processing vast amounts of data, predicting molecular behaviors, and simulating drug interactions with greater speed and accuracy. This part will explore deeper into the role of AI in medicinal chemistry (Figure 3) and look at its impact on the field.

3.1. Drug Design and Discovery

Artificial Intelligence methodologies, including ML and deep learning, significantly accelerate drug discovery. By analyzing extensive chemical libraries and biological data, AI predicts the efficacy and safety of molecules, thereby enhancing the initial stages of drug discovery (13, 14).

3.2. Structure-Activity Relationships

Artificial intelligence models predict how chemical structures relate to biological activities, facilitating the design of molecules with specific therapeutic effects and minimal side effects. These models help identify critical structural features that influence biological activity, thus improving lead compounds (15-18).

3.3. Synthesis Prediction and Optimization

Artificial intelligence predicts efficient synthetic pathways, reducing the resources required for drug synthesis. It also predicts reaction outcomes and identifies novel synthesis routes, streamlining the entire drug development process (19).

3.4. Molecular Docking and Pharmacophores

Artificial intelligence models interactions between drugs and biological targets, aiding in molecular docking and pharmacophore identification. This assists




Figure 1. Different fields of pharmaceutical sciences in which artificial intelligence (AI) can be applied (created with BioRender.com).




Figure 2. Timeline of the development of artificial intelligence (AI) application in pharmaceutical sciences

in discovering new compounds with desired biological activities (20).

3.5. Predictive Absorption, Distribution, Metabolism, Excretion, and Toxicity Modeling

Predicting absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties is crucial in drug discovery. Artificial intelligence significantly aids in this area by providing accurate predictions, essential for assessing new compounds' drug-likeness and potential success (21). The detailed discussion on predictive ADMET modeling has been integrated into

the "Predictive ADMET and PK/PD Modeling" subsection under "AI in Pharmacology and Toxicology."

3.6. Quantitative Structure-Activity Relationship Models

Artificial intelligence-driven quantitative structure-activity relationship (QSAR) models predict the activity of compounds based on their chemical structures, crucial for identifying promising compounds for further analysis (15).

3.7. Chemoinformatics

Artificial intelligence extracts valuable insights from large chemoinformatics databases, identifying patterns




Figure 3. Role of artificial intelligence (AI) in medicinal chemistry



Figure 4. Impact of artificial intelligence (AI) in the field of pharmaceuticals

and relationships between chemical compounds and their biological activities (22).

3.8. Biomarker Identification and Drug Repurposing

Artificial intelligence identifies potential disease-associated biomarkers and discovers new therapeutic applications for existing drugs, facilitating drug repurposing efforts (23). The detailed discussion on biomarker identification and drug repurposing has been integrated into the "Biomarker Discovery, Validation, and Drug Repurposing" subsection under "AI in Pharmaceutical Biotechnology."

3.9. Collaborative Drug Development

Artificial intelligence enhances collaboration among chemists, biologists, and data scientists, expediting the discovery of new medicines (24, 25).

3.10. Relevant Studies

Several studies highlight AI's impact in medicinal chemistry. For example, Harren et al. utilized explainable artificial intelligence (XAI) methods in lead optimization, providing valuable SAR insights. Matsuzaka et al.'s (as cited by Harren et al.) DeepSnap-DL

system improved QSAR predictions (18). Other studies have demonstrated AI's role in synthesis planning, predictive ADMET modeling, and drug repurposing, underscoring the technology's transformative potential (Appendix 1 in Supplementary File).

4. Artificial Intelligence in Pharmaceuticals

Artificial intelligence is profoundly transforming the field of pharmaceuticals by enhancing the development, formulation, and manufacturing of pharmaceutical products. Its capabilities in data analysis, predictive modeling, and automation are driving efficiency, accuracy, and innovation across the industry. In this section, we will discuss how AI is impacting the field of pharmaceuticals (Figure 4).

4.1. Drug Formulation, Design, and Development

Artificial intelligence algorithms evaluate data to predict the stability and compatibility of pharmaceutical ingredients. This technology can improve formulations for controlled release, optimize bioavailability, and minimize side effects, enhancing the entire lifecycle of pharmaceutical products (25-27).

4.2. Predictive Analytics in Drug Development

Artificial intelligence models are used to predict how drug formulations will behave under various conditions, aiding in the assessment of efficacy and stability. This is particularly crucial for understanding the physicochemical properties of drugs, such as solubility and permeability, which are critical factors in pharmacokinetics (PK) and target receptor interactions (28).

4.3. Personalized Pharmaceuticals

Artificial intelligence enables the development of personalized drug formulations tailored to individual patient needs, considering genetic, lifestyle, and medical factors. The push towards personalized medicine is exemplified by initiatives like the precision medicine initiative (PMI) (29). Artificial intelligence also addresses the challenge of providing flexible dosage strengths, crucial for drugs with a narrow therapeutic index, through innovations like data-enriched edible pharmaceuticals (DEEP) (30).

4.4. Process Optimization in Manufacturing

Artificial intelligence tools improve manufacturing processes by predicting ideal conditions, monitoring

quality, and forecasting potential issues, thus enhancing efficiency and reducing costs (31, 32).

4.5. Regulatory Affairs, Quality Control, and Assurance

Artificial intelligence tools streamline regulatory processes and improve quality control in pharmaceutical manufacturing. They automate tasks such as auditing, quality management, dossier filling, and compliance monitoring, ensuring that products meet regulatory standards and identifying impurities quickly (33, 34).

4.6. Supply Chain Management

The role of AI in demand forecasting, inventory management, and distribution optimization is crucial for ensuring timely delivery of pharmaceutical products while avoiding shortages or overstocks (35). The detailed discussion on supply chain management has been integrated into the "Supply Chain Optimization" subsection under "AI in Pharmaceutical Management and Economics."

4.7. Robotic Process Automation

In pharmaceutical manufacturing, robotic process automation (RPA) is employed for repetitive tasks such as packaging and labeling to enhance efficiency and minimize human error (36).

4.8. Nanoformulations

Pharmaceutical nanotechnology utilizes AI to create and refine nano-scale drug delivery systems, which can precisely target specific areas of the body, resulting in more effective treatments with fewer side effects (37).

4.9. Relevant Studies

Examples of AI applications in pharmaceuticals include the Formulation AI platform for *in silico* formulation design, which predicts critical properties of drug formulations, and RPA systems that automate business processes. These technologies demonstrate AI's capability to streamline drug product development and optimize manufacturing processes (38). For detail refer to Appendix 1 in Supplementary File.

5. Artificial Intelligence in Pharmacology and Toxicology

The integration of AI into pharmacology and toxicology marks a significant advancement, offering profound insights into drug effects, safety profiles, and environmental impacts. Artificial intelligence's ability to




Figure 5. Artificial intelligence (AI) in pharmacology and toxicology

manage large datasets, identify patterns, and predict outcomes is revolutionizing these fields, providing a comprehensive understanding of pharmacological research and toxicological risk assessment. This part of the article elucidates the contribution of AI in these fields (Figure 5).

5.1. Drug Action and Response Prediction

Artificial intelligence algorithms analyze complex datasets to predict the pharmacological effects and mechanisms of action of drugs. This capability allows for the development of more targeted and effective treatments by anticipating drug interactions within biological systems (39, 40).

5.2. Toxicity Prediction and Risk Assessment

In toxicology, AI plays a pivotal role by predicting the potential toxicity of substances. By analyzing chemical

structures and historical toxicity data, ML algorithms can forecast the toxicity of new compounds, reducing reliance on extensive in vivo testing (41, 42).

5.3. Predictive Absorption, Distribution, Metabolism, Excretion, and Toxicity and Pharmacokinetics /Pharmacodynamics Modeling

Artificial intelligence significantly contributes to predicting and modeling ADMET properties, crucial in drug discovery. Additionally, AI models simulate PK and pharmacodynamics (PD), helping to understand drug behavior in the body and optimize dosing, ensuring efficacy and safety (43, 44).

5.4. High-throughput Screening

Artificial intelligence accelerates high-throughput screening (HTS) by quickly analyzing vast amounts of pharmacological test data, facilitating the rapid




Figure 6. How artificial intelligence (AI) is being integrated into clinical pharmacy

identification of potential compounds and enhancing the understanding of their pharmacological properties (45). The detailed discussion on HTS has been integrated into the "High-throughput Screening" subsection under "AI in Pharmaceutical Biotechnology."

5.5. Adverse Drug Reaction Prediction

Artificial intelligence can analyze medical records and patient feedback to predict ADRs, helping to ensure drug safety by detecting rare but severe side effects (46).

5.6. Drug Repurposing

By examining existing drugs' characteristics and effects on various biological targets, AI identifies new therapeutic uses for them. This cost-effective method shortens the development time compared to creating entirely new drugs (47). The comprehensive discussion on Drug Repurposing has been integrated into the "AI in Pharmaceutical Biotechnology" section, specifically under the "Biomarker Discovery, Validation, and Drug Repurposing" subsection.

5.7. Biomarker Discovery

Artificial intelligence is instrumental in identifying biomarkers for drug development, diagnosis, and treatment monitoring. This capability fosters the creation of targeted therapies and personalized medicine approaches (48). A detailed discussion is provided in the "Biomarker Discovery, Validation, and Drug Repurposing" subsection in the "AI in Pharmaceutical Biotechnology" section.

5.8. Environmental Toxicology

Artificial intelligence models assess the impact of chemicals on the environment and public health, aiding in the development of safer chemicals and environmental guidelines (49).

5.9. Relevant Studies

Recent research highlights AI's transformative role in pharmacology and toxicology. For instance, studies have explored the prognostic and therapeutic significance of various genes in gastric cancer and the regulatory role of miRNAs in glioblastoma. Machine learning models have predicted clinical responses to anti-epileptic drugs and ADRs, demonstrating the integration of clinical and genetic data. Advances in chemical language models for toxicity prediction and the use of AI in ADMET modeling underscore AI's growing importance in preclinical drug discovery (50, 51). More relevant studies are provided in Appendix 1 in Supplementary File.

6. Artificial Intelligence in Clinical Pharmacy

Artificial intelligence is increasingly being used in clinical pharmacy to aid in providing better patient care. By utilizing AI's capabilities in data analysis, pattern recognition, and forecasting, clinical pharmacy can implement more accurate, efficient, and customized methods. Artificial intelligence can enhance various aspects of clinical pharmacy, including drug dispensing and patient counseling, and this section provides a detailed analysis of how AI is being integrated into clinical pharmacy (Figure 6).

6.1. Personalized Medicine

Artificial intelligence algorithms are used to analyze patient data, including genetic information, to customize drug therapies. This personalized approach ensures that patients are prescribed medications that are most effective for their unique profiles, leading to better treatment outcomes and fewer adverse reactions (52).

6.2. Drug Interaction and Safety Analysis

Artificial intelligence systems are capable of rapidly analyzing a patient's medication list to identify possible drug-drug interactions and contraindications. This process helps to lower the chance of ADRs and improve patient safety (39).

6.3. Dose Optimization

Artificial intelligence aids in determining the most suitable dosage of medication for individual patients. It considers various factors such as age, weight, kidney function, and specific patient conditions to suggest doses that optimize efficacy while minimizing side effects (53).

6.4. Pharmacovigilance

Artificial intelligence tools monitor and analyze data from different sources to identify possible ADRs and medication errors, providing a proactive approach to pharmacovigilance. This process helps to enhance patient safety and improve drug profiles (54).

6.5. Patient Adherence and Monitoring

Applications and devices powered by AI can track patient adherence to medication regimens, send reminders, and notify healthcare providers if patients are not following prescribed therapies (55).

6.6. Automated Dispensing and Inventory Management

Artificial intelligence enhances the efficiency of pharmacy operations by automating dispensing processes and managing inventory. This not only saves time but also reduces human error in dispensing medications (56, 57).

6.7. Clinical Decision Support Systems

Artificial intelligence-powered clinical decision support systems (CDSS) provide pharmacists and healthcare providers with evidence-based guidance and

recommendations, assisting in clinical decision-making and ensuring the best patient care (58).

6.8. Telepharmacy and Remote Consultations

Artificial intelligence facilitates advanced telepharmacy services by enabling patients to receive consultations and medication management advice remotely, increasing accessibility to pharmaceutical care (59).

6.9. Research and Development

Artificial intelligence is utilized in clinical pharmacy research to scrutinize clinical trial data, patient outcomes, and treatment efficacies, advancing better therapeutic protocols and drug policies (60, 61).

6.10. Relevant Studies

Yin et al. reviewed 51 studies from 2010 to 2020, highlighting AI's use in clinical settings for screening, diagnosis, risk analysis, and treatment of various conditions (62). The xDECIDE system exemplifies AI's role in personalized oncology care by integrating real-world evidence and expert knowledge (63). Other studies demonstrate AI's potential in personalized medicine and drug repurposing, such as the DRIAD framework for Alzheimer's disease. More studies can be found in Appendix 1 in Supplementary File.

7. Artificial Intelligence in Pharmaceutical Biotechnology

Artificial intelligence is increasingly integral to pharmaceutical biotechnology, revolutionizing research methodologies and expediting the development of biopharmaceutical products. Its capabilities in data analysis, predictive modeling, and process optimization are particularly valuable for navigating the complexities of biological systems and biotechnological processes. This section outlines AI's use in pharmaceutical biotechnology (Figure 7).

7.1. Biopharmaceutical Drug Discovery

Artificial intelligence algorithms identify potential biopharmaceutical drugs such as antibodies, vaccines, and gene therapies. By analyzing biological data, AI can predict the efficacy and safety of these complex molecules, significantly accelerating the discovery process (64-66). For example, a systems biology approach has provided insights into gastric cancer pathogenesis, revealing complex gene networks and pathways (67).




Figure 7. Artificial intelligence (AI)'s use in pharmaceutical biotechnology

7.2. Protein Structure Prediction and Analysis

Artificial intelligence, especially deep learning models, predicts the 3D structures of proteins, essential for understanding protein functions and designing drugs that target these proteins accurately (68).

7.3. Genomic and Genetic Data Analysis

Artificial intelligence analyzes vast genomic data to identify genetic markers associated with diseases and potential therapeutic targets, aiding in the development of personalized medicine strategies and targeted therapies (69).

7.4. Optimization of Bioprocessing

Artificial intelligence optimizes biotechnological processes, including fermentation, cell culture, and purification. Machine Learning models predict optimal conditions, improving efficiency and yield (70).

7.5. High-throughput Screening

Artificial intelligence plays a crucial role in accelerating HTS in both drug discovery and

biopharmaceutical research. By quickly analyzing the outcomes of thousands of pharmacological tests, AI speeds up the identification of potential compounds and enhances the understanding of their pharmacological properties. Additionally, AI's ability to rapidly analyze data from a wide range of experiments helps identify potential therapeutic targets and biological compounds more efficiently. This integration of AI in HTS makes the process more streamlined and effective, significantly contributing to advancements in both pharmacology and biopharmaceutical development (45).

7.6. Biosimulation and Predictive Modeling

Artificial intelligence-powered biosimulation models mimic biological processes and drug interactions, providing insights into drug interactions, side effects, and potential therapeutic pathways (71).

7.7. Biomarker Discovery, Validation, and Drug Repurposing

Artificial intelligence plays a crucial role in enhancing both the discovery and validation of biomarkers, as well as facilitating drug repurposing efforts. By analyzing large datasets, AI can efficiently and



Figure 8. Role of artificial intelligence (AI) in pharmaceutical nanotechnology

accurately identify potential disease-associated biomarkers, essential for diagnosing diseases and developing targeted therapies. Furthermore, AI can analyze the characteristics and effects of existing drugs on various biological targets to identify novel therapeutic applications. This approach to drug repurposing is not only cost-efficient but also significantly reduces the development timeline compared to creating entirely new drugs. Utilizing AI in this manner accelerates the drug development process and enhances the potential for finding effective treatments for various conditions (72, 73).

7.8. Relevant Studies

Noteworthy studies include Sumitomo Dainippon Pharma's collaboration with Exscientia, which rapidly discovered DSP-1181 for obsessive-compulsive disorder. Artificial intelligence algorithms have also been used to predict the immunogenicity of biologic candidates, improving clinical translation success rates (74). Furthermore, AI is advancing cell and gene therapies by identifying optimal targets and designing delivery vehicles. In COVID-19 research, AI-based feature selection methods have provided insights into potential biomarkers (75). Additionally, AI's role in drug repurposing and biopharmaceutical innovation is expanding globally, with numerous companies exploring its applications (76). More studies are provided in Appendix 1 in Supplementary File.

8. Artificial intelligence in Pharmaceutical Nanotechnology

Artificial intelligence is significantly advancing pharmaceutical nanotechnology, particularly in the development and application of nanomedicines. Its capabilities in data analysis, predictive modeling, and design optimization are ideally suited for the complex

requirements of nanotechnology. This section will explore the role of AI in this field (Figure 8).

8.1. Design and Development of Nanocarriers

Artificial intelligence algorithms are increasingly used to design nanocarriers for drug delivery, predicting optimal dimensions, shapes, and surface properties to improve targeting accuracy and reduce toxicity, thereby enhancing therapeutic effectiveness (77).

8.2. Targeted Drug Delivery Systems

Artificial intelligence aids in creating targeted drug delivery systems, predicting interactions between nanoparticles and biological systems to enhance precision in drug targeting, thereby minimizing side effects and improving efficacy (37).

8.3. High-throughput Screening in Nanoparticle Research

Artificial intelligence facilitates the rapid analysis of various nanoparticle formulations for drug delivery and imaging, streamlining the HTS process in nanoparticle research (78).

8.4. Predictive Toxicology

Artificial intelligence models are critical for predicting the potential toxicity of nanoparticles, analyzing physicochemical properties to assess biocompatibility and environmental impact, ensuring the safety of nanomedicines (79).

8.5. Enhancing Solubility and Stability of Drugs

Artificial intelligence assists in improving the solubility and stability of poorly soluble drugs through nanoformulation, predicting ideal nanocarriers and formulation techniques to enhance drug solubility (77).



Figure 9. The impact of artificial intelligence (AI) on pharmacognosy

8.6. Nanodiagnostic Applications

Artificial intelligence contributes to the development of nanotechnology-based sensors and diagnostic devices, including nanoscale biosensors and diagnostic assays, for the early and accurate detection of diseases (80, 81).

8.7. Personalized Nanomedicine

With AI, pharmaceutical nanotechnology is moving towards personalized medicine, using patient-specific data to tailor nanomedicine formulations, thereby maximizing therapeutic outcomes (82).

8.8. Process Optimization in Nanoparticle Manufacturing

Artificial intelligence is used to optimize nanoparticle manufacturing processes, improving scalability, consistency, and quality control in production (83).

8.9. Relevant Studies

In collaboration with AstraZeneca, researchers at Cardiff University designed AI-driven nanoparticles for delivering mRNA to cancer cells, demonstrating superior efficacy compared to other prototypes (84, 85). A study by Banaye Yazdipour et al. (86) employed AI tools like Random Forest and Support Vector Machine to

predict the toxicity of metal oxide and metallic nanoparticles, offering a fast and cost-effective alternative to traditional toxicity testing methods. Numerous studies highlight the potential of AI in accelerating drug development and discovering new treatments, with interdisciplinary collaborations among pharmaceutical scientists, computer scientists, statisticians, and physicians playing a crucial role (24, 25). More relevant studies are provided in Appendix 1 in Supplementary File.

9. Artificial Intelligence in Pharmacognosy

The identification and examination of natural chemicals are changing because of the incorporation of AI into pharmacognosy, the study of medications obtained from natural sources. This discipline benefits greatly from AI's ability to handle big datasets, anticipate compound qualities, and clarify intricate biological connections. This section discusses the impact of AI on pharmacognosy (Figure 9).

9.1. Natural Product Drug Discovery

Artificial intelligence expedites the identification and analysis of bioactive compounds from natural sources such as marine organisms, fungi, and plants. Machine Learning algorithms can swiftly screen large natural product libraries, identifying potential

therapeutic compounds more efficiently than traditional methods (87).

9.2. Structure-Elucidation of Natural Compounds

Using spectral data, Artificial Intelligence can anticipate the structure of new natural substances. Understanding the bioactivity of these molecules and accelerating their development into medications depend on this quick structural elucidation (88).

9.3. Ethnobotanical Data Analysis

Artificial intelligence algorithms are increasingly used to analyze ethnobotanical data, merging traditional medicinal knowledge with modern drug discovery. This involves identifying potential drug leads by studying the historical and cultural uses of natural substances (89).

9.4. High-throughput Screening in Natural Product Research

In pharmacognosy, AI improves the effectiveness of HTS techniques by enabling the quick screening of multiple natural extracts and compounds against different biological targets (90).

9.5. Predictive Metabolomics

Artificial intelligence plays a significant role in metabolomics research by predicting the metabolic pathways of natural products and elucidating their mechanisms of action, which is essential for assessing their medicinal potential (91).

9.6. Quality Control and Standardization

Artificial intelligence applications are vital for the quality control and standardization of herbal medicines. They analyze chemical profiles and detect contaminants, ensuring the safety and reliability of natural products (92).

9.7. Personalized Medicine with Natural Products

Scientists are creating AI models to customize natural product-based treatments for individual patients. This involves assessing patient-specific information to anticipate the reactions to herbal medicines (52, 93).

9.8. Biodiversity and Conservation Data Analysis

Artificial intelligence helps in scrutinizing biodiversity data to recognize and preserve medicinal

plants and other organisms that are reservoirs of precious natural compounds (94).

9.9. Relevant Studies

Desai et al. highlighted AI's role in enhancing pharmacognostic performance, particularly in identifying active compounds and optimizing extraction processes (95). Gallicchio et al. developed MproPred, a web application utilizing ML to predict compound bioactivity against SARS-CoV-2's main protease, showing significant potential for COVID-19 drug development (96). More relevant studies can be found in Appendix 1 in Supplementary File.

10. Artificial Intelligence in Pharmaceutical Management and Economics

Artificial intelligence is playing a transformative role in pharmaceutical management and economics, offering solutions to enhance efficiency, decision-making, and economic outcomes. Its capabilities in analyzing complex datasets, predicting market trends, and optimizing operational processes are particularly beneficial in addressing the unique challenges faced by the pharmaceutical industry. In this part, an exploration of AI's role in this area is provided (Figure 10).

10.1. Supply Chain Optimization

Artificial intelligence improves the management of pharmaceutical supply chains by predicting demand, controlling inventory, and managing distribution logistics. This leads to reduced waste, timely product availability, and cost reduction, as demonstrated by studies showcasing optimized inventory levels and streamlined distribution processes (97).

10.2. Market Analysis and Drug Pricing Strategies

Artificial intelligence is crucial in analyzing pharmaceutical market trends and consumer behavior, helping companies make informed decisions on drug marketing, pricing, and sales. It predicts the market potential of new drugs and assesses the impact of pricing strategies on market share and profitability (98).

10.3. Health Economics and Outcomes Research

Artificial intelligence models analyze large datasets in health economics and outcomes research (HEOR), evaluating the value of pharmaceutical products based on clinical outcomes, quality of life, and cost-effectiveness. This analysis informs decisions on drug development priorities and healthcare policies (99).



Figure 10. Artificial intelligence (AI) in pharmaceutical management and economics

10.4. Pharmaceutical Manufacturing Efficiency

Artificial intelligence enhances manufacturing efficiency by monitoring production lines, predicting equipment malfunctions (predictive maintenance), and optimizing production schedules. This results in reduced downtime, cost savings, and improved operational efficiency (100).

10.5. Regulatory Compliance and Risk Management

Artificial intelligence tools ensure compliance with regulatory standards through automated monitoring and reporting. They also assist in risk management by identifying potential regulatory issues early in the drug development process (100).

10.6. Data-Driven Decision Making

Artificial intelligence facilitates strategic decision-making in pharmaceutical management by analyzing clinical trial data, patient outcomes, and market research, providing valuable insights that guide more informed and effective decisions (100).

10.7. Patient Engagement and Market Access Strategies

Artificial intelligence-powered platforms enhance patient engagement and support market access strategies by personalizing patient communication and

optimizing patient support programs, leading to better patient outcomes and stronger engagement (100).

10.8. Competitive Intelligence

Artificial intelligence gathers and analyzes competitive intelligence, allowing pharmaceutical companies to stay ahead in a competitive market by understanding competitors' strategies, market positions, and product developments (5).

10.9. Relevant Studies

Studies highlight AI's role in improving manufacturing processes, such as predicting ideal production conditions and monitoring drug quality (31, 32). Artificial intelligence's application in supply chain optimization has led to significant efficiency and cost improvements, as seen in studies focusing on the US pharmaceutical supply chain post-Hurricane Maria (101). More studies are provided in Appendix 1 in Supplementary File.

11. Challenges, Limitations, Potential Drawbacks, and Ethical Considerations of Artificial Intelligence

The integration of AI into pharmaceutical sciences offers significant opportunities alongside notable challenges and ethical considerations. Among the primary issues are data privacy and confidentiality, as AI often requires handling sensitive patient data.



Figure 11. Future perspectives of using artificial intelligence (AI) in the pharmaceutical field

Safeguarding this information against breaches and unauthorized access, while complying with regulations like GDPR and HIPAA, is crucial (100). Bias and fairness in AI algorithms are also major concerns; AI systems can perpetuate existing disparities if trained on biased data, leading to unequal treatment in drug development and patient care (102).

Transparency and explainability are critical, especially for deep learning models often regarded as 'black boxes' due to their complexity. This lack of transparency can hinder trust and accountability, particularly in healthcare, where understanding the basis for AI-driven decisions is vital (103). Regulatory compliance is another challenge, as AI technologies must adhere to stringent pharmaceutical regulations and standards, requiring validation for clinical use and navigation of complex regulatory pathways (104).

Ethical issues also arise, particularly regarding data privacy, informed consent, and the potential misuse of AI. Clear guidelines and consent processes are necessary to ensure ethical AI deployment (105). The dependency on AI could also lead to a skill gap in the pharmaceutical workforce, necessitating ongoing education and training to keep professionals adept in collaborating with AI technologies (106, 107).

Intellectual property rights pose another challenge, as determining ownership of AI-generated discoveries can be complex (107). The quality and reliability of data are crucial for AI accuracy, yet gathering and maintaining high-quality datasets is challenging in pharmaceutical sciences (108). Additionally, the high cost of integrating AI solutions may limit accessibility, particularly in low-resource settings, potentially widening global healthcare disparities (109).

Overall, while AI promises to revolutionize pharmaceutical sciences, it is essential to address these challenges and ethical considerations to ensure that its benefits are realized responsibly and equitably. The focus should be on leveraging AI's potential in a manner that is fair and beneficial for all stakeholders, avoiding exacerbation of existing inequalities and ensuring robust, ethical AI deployment in healthcare.

12. Conclusion and Future Perspectives

The future integration of AI in pharmaceutical fields (Figure 11) promises significant innovation, efficiency, and personalized medicine. Artificial intelligence's capabilities in analyzing large datasets and simulating biological processes can make drug discovery and development more efficient and cost-effective,

potentially halving timelines and reducing costs by up to 40% by 2030 (110). This technology is also expected to enable highly personalized treatment plans, optimize therapeutic outcomes, and minimize side effects, with widespread adoption anticipated in the next decade (111).

Artificial intelligence's role in early disease detection and forecasting treatment responses will revolutionize diagnostic laboratories, increasing precision and speed (112). It will also streamline manufacturing and supply chain processes, potentially boosting operational efficiency by 30%. Furthermore, AI can democratize access to advanced healthcare, reducing disparities between high-resource and low-resource settings (113).

As AI systems evolve, they will continuously learn and adapt, ensuring ongoing innovation in pharmaceutical practices. By 2035, AI is expected to be seamlessly integrated into global healthcare systems, necessitating robust ethical and regulatory frameworks to ensure patient safety, data privacy, and equitable access to AI-driven therapies. Increased collaboration among AI experts, pharmaceutical scientists, healthcare providers, and policymakers will be crucial (6, 113).

Investment in education and training is essential to equip professionals with the skills to work alongside AI technologies (114). While the potential of AI in pharmaceuticals is vast, it is crucial to address ethical, regulatory, and practical challenges to ensure responsible and equitable application of these technologies, ultimately improving global healthcare (115).

Acknowledgements

We would like to acknowledge the Iran University of Medical Sciences for their support.

Supplementary Material

Supplementary material(s) is available [here](#) [To read supplementary materials, please refer to the journal website and open PDF/HTML].

Footnotes

Authors' Contribution: N. M. D.: Conceptualized the study; N. M. D. and M. S. R. R.: Conducted the investigation; N. M. D.: Supervised the manuscript preparation; N. M. D.: Drafted the original manuscript; M. S. R. R.: Reviewed and edited the manuscript; N. M. D.:

Prepared the figures. All authors reviewed and approved the final manuscript.

Conflict of Interests Statement: The authors declare that they have no competing interests relevant to the content of this article.

Data Availability: The data presented in this study are uploaded as a supplementary file during submission and are openly available to readers upon request.

Funding/Support: This study did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

References

- Bhattamisra SK, Banerjee P, Gupta P, Mayuren J, Patra S, Candasamy M. Artificial Intelligence in Pharmaceutical and Healthcare Research. *Big Data and Cognitive Computing*. 2023;7(1). <https://doi.org/10.3390/bdcc7010010>.
- Lu M, Yin J, Zhu Q, Lin G, Mou M, Liu F, et al. Artificial Intelligence in Pharmaceutical Sciences. *Engineering*. 2023;27:37-69. <https://doi.org/10.1016/j.eng.2023.01.014>.
- Kaur S, Singla J, Nkenyereye L, Jha S, Prashar D, Joshi GP, et al. Medical Diagnostic Systems Using Artificial Intelligence (AI) Algorithms: Principles and Perspectives. *IEEE Access*. 2020;8:228049-69. <https://doi.org/10.1109/ACCESS.2020.3042273>.
- Sun D, Gao W, Hu H, Zhou S. Why 90% of clinical drug development fails and how to improve it? *Acta Pharm Sin B*. 2022;12(7):3049-62. [PubMed ID: 35865092]. [PubMed Central ID: PMC9293739]. <https://doi.org/10.1016/j.apsb.2022.02.002>.
- Blanco-Gonzalez A, Cabezon A, Seco-Gonzalez A, Conde-Torres D, Antelo-Riveiro P, Pineiro A, et al. The Role of AI in Drug Discovery: Challenges, Opportunities, and Strategies. *Pharmaceuticals (Basel)*. 2023;16(6). [PubMed ID: 37375838]. [PubMed Central ID: PMC10302890]. <https://doi.org/10.3390/phi16060891>.
- Dave P. How AI Can Revolutionize the Pharmaceutical Industry. *J Drug Delivery Therapeutics*. 2024;14(6):179-83. <https://doi.org/10.22270/jddt.v14i6.6657>.
- Patel L, Shukla T, Huang X, Ussery DW, Wang S. Machine Learning Methods in Drug Discovery. *Mol*. 2020;25(22). [PubMed ID: 33198233]. [PubMed Central ID: PMC7696134]. <https://doi.org/10.3390/molecules25225277>.
- Gentleman R, Carey VJ. Unsupervised Machine Learning. In: Hahne F, Huber W, Gentleman R, Falcon S, editors. *Bioconductor Case Studies*. New York, NY: Springer New York; 2008. p. 137-57. https://doi.org/10.1007/978-0-387-77240-0_10.
- Dana D, Gadhya SV, St Surin LG, Li D, Naaz F, Ali Q, et al. Deep Learning in Drug Discovery and Medicine; Scratching the Surface. *Mol*. 2018;23(9). [PubMed ID: 30231499]. [PubMed Central ID: PMC6225282]. <https://doi.org/10.3390/molecules23092384>.
- Zeng Z, Shi H, Wu Y, Hong Z. Survey of Natural Language Processing Techniques in Bioinformatics. *Comput Math Methods Med*. 2015;2015:674296. [PubMed ID: 26525745]. [PubMed Central ID: PMC4615216]. <https://doi.org/10.1155/2015/674296>.
- Szepesvári C. *Algorithms for Reinforcement Learning*. New York City, USA: Springer International Publishing; 2022.
- Struble TJ, Alvarez JC, Brown SP, Chytil M, Cisar J, DesJarlais RL, et al. Current and Future Roles of Artificial Intelligence in Medicinal Chemistry Synthesis. *J Med Chem*. 2020;63(16):8667-82. [PubMed ID:

- 32243158]. [PubMed Central ID: PMC7457232]. <https://doi.org/10.1021/acs.jmedchem.9b02120>.
13. Zhuang D, Ibrahim AK. Deep Learning for Drug Discovery: A Study of Identifying High Efficacy Drug Compounds Using a Cascade Transfer Learning Approach. *Appl Sci*. 2021;**11**(17). <https://doi.org/10.3390/app11177772>.
 14. Askr H, Elgeldawi E, Aboul Ella H, Elshaier Y, Gomaa MM, Hassanien AE. Deep learning in drug discovery: an integrative review and future challenges. *Artif Intell Rev*. 2023;**56**(7):5975-6037. [PubMed ID: 36415536]. [PubMed Central ID: PMC9669545]. <https://doi.org/10.1007/s10462-022-10306-1>.
 15. Tsou LK, Yeh SH, Ueng SH, Chang CP, Song JS, Wu MH, et al. Comparative study between deep learning and QSAR classifications for TNBC inhibitors and novel GPCR agonist discovery. *Sci Rep*. 2020;**10**(1):16771. [PubMed ID: 33033310]. [PubMed Central ID: PMC7545175]. <https://doi.org/10.1038/s41598-020-73681-1>.
 16. Ning X, Karypis G. In silico structure-activity-relationship (SAR) models from machine learning: a review. *Drug Dev Res*. 2010;**72**(2):138-46. <https://doi.org/10.1002/ddr.20410>.
 17. Mao J, Akhtar J, Zhang X, Sun L, Guan S, Li X, et al. Comprehensive strategies of machine-learning-based quantitative structure-activity relationship models. *iScience*. 2021;**24**(9):103052. [PubMed ID: 34553136]. [PubMed Central ID: PMC8441174]. <https://doi.org/10.1016/j.isci.2021.103052>.
 18. Harren T, Matter H, Hessler G, Rarey M, Grebner C. Interpretation of Structure-Activity Relationships in Real-World Drug Design Data Sets Using Explainable Artificial Intelligence. *J Chem Inf Model*. 2022;**62**(3):447-62. [PubMed ID: 35080887]. <https://doi.org/10.1021/acs.jcim.1c01263>.
 19. Thakkar A, Johansson S, Jorner K, Buttar D, Reymond J, Engkvist O. Artificial intelligence and automation in computer aided synthesis planning. *Reaction Chem Engin*. 2021;**6**(1):27-51. <https://doi.org/10.1039/d0re00340a>.
 20. Rusinko A, Rezaei M, Friedrich L, Buchstaller H, Kuhn D, Ghogare A. AIDDISON: Empowering Drug Discovery with AI/ML and CADD Tools in a Secure, Web-Based SaaS Platform. *J Chem Inform Mod*. 2024;**64**(1):3-8. <https://doi.org/10.1021/acs.jcim.3c01016>.
 21. Pu L, Naderi M, Liu T, Wu H, Mukhopadhyay S, Brylinski M. eToxPred: a machine learning-based approach to estimate the toxicity of drug candidates. *BMC Pharmacol Toxicol*. 2019;**20**(1):2. <https://doi.org/10.1186/s40360-018-0282-6>.
 22. Niazi SK, Mariam Z. Recent Advances in Machine-Learning-Based Chemoinformatics: A Comprehensive Review. *Int J Mol Sci*. 2023;**24**(14). [PubMed ID: 37511247]. [PubMed Central ID: PMC10380192]. <https://doi.org/10.3390/ijms241411488>.
 23. Rodriguez S, Hug C, Todorov P, Moret N, Boswell SA, Evans K, et al. Machine learning identifies candidates for drug repurposing in Alzheimer's disease. *Nat Commun*. 2021;**12**(1):1033. [PubMed ID: 33589615]. [PubMed Central ID: PMC7884393]. <https://doi.org/10.1038/s41467-021-21330-0>.
 24. Farghali H, Kutinova Canova N, Arora M. The potential applications of artificial intelligence in drug discovery and development. *Physiol Res*. 2021;**70**(Suppl4):S715-22. [PubMed ID: 35199553]. [PubMed Central ID: PMC9054182]. <https://doi.org/10.33549/physiolres.934765>.
 25. Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade RK. Artificial intelligence in drug discovery and development. *Drug Discov Today*. 2021;**26**(1):80-93. [PubMed ID: 33099022]. [PubMed Central ID: PMC7577280]. <https://doi.org/10.1016/j.drudis.2020.10.010>.
 26. Srivastava V, Parveen B, Parveen R, Noorain. Artificial Intelligence in Drug Formulation and Development: Applications and Future Prospects. *Curr Drug Metab*. 2023;**24**(9):622-34. [PubMed ID: 3779408]. <https://doi.org/10.2174/0113892002265786230921062205>.
 27. Hassanzadeh P, Atyabi F, Dinarvand R. The significance of artificial intelligence in drug delivery system design. *Adv Drug Deliv Rev*. 2019;**151-152**:169-90. [PubMed ID: 31071378]. <https://doi.org/10.1016/j.addr.2019.05.001>.
 28. Singh S, Gupta H, Sharma P, Sahi S. Advances in Artificial Intelligence (AI)-assisted approaches in drug screening. *Artificial Intelligence Chemistry*. 2024;**2**(1):100039. <https://doi.org/10.1016/j.aichem.2023.100039>.
 29. Tahara K. Pharmaceutical formulation and manufacturing using particle/powder technology for personalized medicines. *Adv Powder Technol*. 2020;**31**(1):387-92. <https://doi.org/10.1016/j.apt.2019.10.031>.
 30. Handa M, Afzal O, Beg S, Nashik Sanap S, Kaundal RK, Verma RK, et al. Harnessing personalized tailored medicines to digital-based data-enriched edible pharmaceuticals. *Drug Discov Today*. 2023;**28**(5):103555. [PubMed ID: 36931386]. <https://doi.org/10.1016/j.drudis.2023.103555>.
 31. Liu P, Jin H, Chen Y, Wang D, Yan H, Wu M, et al. Process analytical technologies and self-optimization algorithms in automated pharmaceutical continuous manufacturing. *Chinese Chemical Letters*. 2024;**35**(3). <https://doi.org/10.1016/j.ccllet.2023.108877>.
 32. Kehayov M, Holder L, Koch V. Application of artificial intelligence technology in the manufacturing process and purchasing and supply management. *Procedia Computer Sci*. 2022;**200**:1209-17. <https://doi.org/10.1016/j.procs.2022.01.321>.
 33. Patil RS, Kulkarni SB, Gaikwad VL. Artificial intelligence in pharmaceutical regulatory affairs. *Drug Discov Today*. 2023;**28**(9):103700. [PubMed ID: 37442291]. <https://doi.org/10.1016/j.drudis.2023.103700>.
 34. Coito T, Martins MS, Firme B, Figueiredo J, Vieira SM, Sousa JM. Assessing the impact of automation in pharmaceutical quality control labs using a digital twin. *J Manufacturing Syst*. 2022;**62**:270-85. <https://doi.org/10.1016/j.jmsys.2021.11.014>.
 35. Albayrak Ünal Ö, Erkayman B, Usanmaz B. Applications of Artificial Intelligence in Inventory Management: A Systematic Review of the Literature. *Arch Computational Methods Engineering*. 2023;**30**(4):2605-25. <https://doi.org/10.1007/s11831-022-09879-5>.
 36. Lievano-Martínez FA, Fernández-Ledesma JD, Burgos D, Branch-Bedoya JW, Jimenez-Builes JA. Intelligent Process Automation: An Application in Manufacturing Industry. *Sustainability*. 2022;**14**(14). <https://doi.org/10.3390/su14148804>.
 37. Das KP, J. C. Nanoparticles and convergence of artificial intelligence for targeted drug delivery for cancer therapy: Current progress and challenges. *Front Med Technol*. 2022;**4**:1067144. [PubMed ID: 36688144]. [PubMed Central ID: PMC9853978]. <https://doi.org/10.3389/fmedt.2022.1067144>.
 38. Dong J, Wu Z, Xu H, Ouyang D. FormulationAI: a novel web-based platform for drug formulation design driven by artificial intelligence. *Briefings in Bioinformatics*. 2024;**25**(1):bbad419. <https://doi.org/10.1093/bib/bbad419>.
 39. Zhang Y, Deng Z, Xu X, Feng Y, Junliang S. Application of Artificial Intelligence in Drug-Drug Interactions Prediction: A Review. *J Chem Inf Model*. 2024;**64**(7):2158-73. [PubMed ID: 37458400]. <https://doi.org/10.1021/acs.jcim.3c00582>.
 40. He D, Liu Q, Wu Y, Xie L. A context-aware deconfounding autoencoder for robust prediction of personalized clinical drug response from cell-line compound screening. *Nat Mach Intell*. 2022;**4**(10):879-92. [PubMed ID: 38895093]. [PubMed Central ID: PMC1185412]. <https://doi.org/10.1038/s42256-022-00541-0>.
 41. Hartung T. Artificial intelligence as the new frontier in chemical risk assessment. *Front Artif Intell*. 2023;**6**:1269932. [PubMed ID: 37915539]. [PubMed Central ID: PMC10616238]. <https://doi.org/10.3389/frai.2023.1269932>.

42. Cavasotto CN, Scardino V. Machine Learning Toxicity Prediction: Latest Advances by Toxicity End Point. *ACS Omega*. 2022;7(51):47536-46. [PubMed ID: 36591139]. [PubMed Central ID: PMC9798519]. <https://doi.org/10.1021/acsomega.2c05693>.
43. Pawar V, Shinde A, Mali D, Gaikwad D, Tamboli F, Patil A. Harnessing the Power of AI in Pharmacokinetics and Pharmacodynamics: A Comprehensive Review. *Int J Pharmaceutical Quality Assurance*. 2023;14(2):426-39. <https://doi.org/10.25258/ijpqa.14.2.31>.
44. Chaturvedula A, Calad-Thomson S, Liu C, Sale M, Gattu N, Goyal N. Artificial Intelligence and Pharmacometrics: Time to Embrace, Capitalize, and Advance? *CPT Pharmacometrics Syst Pharmacol*. 2019;8(7):440-3. [PubMed ID: 31006175]. [PubMed Central ID: PMC6657004]. <https://doi.org/10.1002/psp4.12418>.
45. Dreiman GHS, Bictash M, Fish PV, Griffin L, Svensson F. Changing the HTS Paradigm: AI-Driven Iterative Screening for Hit Finding. *SLAS Discov*. 2021;26(2):257-62. [PubMed ID: 32808550]. [PubMed Central ID: PMC7838329]. <https://doi.org/10.1177/2472555220949495>.
46. Yang S, Kar S. Application of artificial intelligence and machine learning in early detection of adverse drug reactions (ADRs) and drug-induced toxicity. *Artificial Intelligence Chemistry*. 2023;1(2):100011. <https://doi.org/10.1016/j.aichem.2023.100011>.
47. Pun FW, Ozerov IV, Zhavoronkov A. AI-powered therapeutic target discovery. *Trends Pharmacol Sci*. 2023;44(9):561-72. [PubMed ID: 37479540]. <https://doi.org/10.1016/j.tips.2023.06.010>.
48. Zhavoronkov A. Artificial Intelligence for Drug Discovery, Biomarker Development, and Generation of Novel Chemistry. *Mol Pharm*. 2018;15(10):4311-3. [PubMed ID: 30269508]. <https://doi.org/10.1021/acs.molpharmaceut.8b00930>.
49. Jeong J, Choi J. Artificial Intelligence-Based Toxicity Prediction of Environmental Chemicals: Future Directions for Chemical Management Applications. *Environ Sci Technol*. 2022;56(12):7532-43. [PubMed ID: 35666838]. <https://doi.org/10.1021/acs.est.1c07413>.
50. Khoshdel F, Mottaghi-Dastjerdi N, Yazdani F, Salehi S, Ghorbani A, Montazeri H, et al. CTGF, FN1, IL-6, THBS1, and WISPI genes and PI3K-Akt signaling pathway as prognostic and therapeutic targets in gastric cancer identified by gene network modeling. *Discover Oncol*. 2024;15(1):344.
51. Amerizadeh F, Rahmani F, Ghorbani A, Mottaghi-Dastjerdi N, Bazyari MJ, Rouhani J, et al. A Prospective to Regulatory Role of Mirnas on Wnt/B-Catenin Signaling and its Crosstalk to the Other Cellular Pathways in Tumorigenesis of Glioblastoma by a Systems Biology Approach. *SSRN*. 2023; **Preprint**.
52. Schork NJ. Artificial Intelligence and Personalized Medicine. *Cancer Treat Res*. 2019;178:265-83. [PubMed ID: 31209850]. [PubMed Central ID: PMC7580505]. https://doi.org/10.1007/978-3-030-16391-4_11.
53. McCollough CH, Leng S. Use of artificial intelligence in computed tomography dose optimisation. *Ann ICRP*. 2020;49(1_suppl):113-25. [PubMed ID: 32870019]. <https://doi.org/10.1177/0146645320940827>.
54. Murali K, Kaur S, Prakash A, Medhi B. Artificial intelligence in pharmacovigilance: Practical utility. *Indian J Pharmacol*. 2019;51(6):373-6. [PubMed ID: 32029958]. [PubMed Central ID: PMC6984023]. https://doi.org/10.4103/ijp.IJP_814_19.
55. Babel A, Taneja R, Mondello Malvestiti F, Monaco A, Donde S. Artificial Intelligence Solutions to Increase Medication Adherence in Patients With Non-communicable Diseases. *Front Digit Health*. 2021;3:669869. [PubMed ID: 34713142]. [PubMed Central ID: PMC8521858]. <https://doi.org/10.3389/fgdth.2021.669869>.
56. Raza MA, Aziz S, Noreen M, Saeed A, Anjum I, Ahmed M, et al. Artificial Intelligence (AI) in Pharmacy: An Overview of Innovations. *Innov Pharm*. 2022;13(2). [PubMed ID: 36654703]. [PubMed Central ID: PMC9836757]. <https://doi.org/10.24926/ijp.v13i2.4839>.
57. Chalasani SH, Syed J, Ramesh M, Patil V, Pramod Kumar TM. Artificial intelligence in the field of pharmacy practice: A literature review. *Explor Res Clin Soc Pharm*. 2023;12:100346. [PubMed ID: 37885437]. [PubMed Central ID: PMC10598710]. <https://doi.org/10.1016/j.rcsop.2023.100346>.
58. Sloane EB, Silva RJ. Artificial intelligence in medical devices and clinical decision support systems. *Clinical engineering handbook*. Amsterdam, Netherlands: Elsevier; 2020. p. 556-68.
59. Sharma S, Rawal R, Shah D. Addressing the challenges of AI-based telemedicine: Best practices and lessons learned. *J Educ Health Promot*. 2023;12:338. [PubMed ID: 38023098]. [PubMed Central ID: PMC10671014]. https://doi.org/10.4103/jehp.jehp_402_23.
60. Kolluri S, Lin J, Liu R, Zhang Y, Zhang W. Machine Learning and Artificial Intelligence in Pharmaceutical Research and Development: a Review. *Aaps j*. 2022;24(1):19. [PubMed ID: 34984579]. [PubMed Central ID: PMC8726514]. <https://doi.org/10.1208/s12248-021-00644-3>.
61. Ranchon F, Chanoine S, Lambert-Lacroix S, Bosson JL, Moreau-Gaudry A, Bedouch P. Development of artificial intelligence powered apps and tools for clinical pharmacy services: A systematic review. *Int J Med Inform*. 2023;172:104983. [PubMed ID: 36724730]. <https://doi.org/10.1016/j.ijmedinf.2022.104983>.
62. Yin J, Ngiam KY, Teo HH. Role of Artificial Intelligence Applications in Real-Life Clinical Practice: Systematic Review. *J Med Internet Res*. 2021;23(4). e25759. [PubMed ID: 33885365]. [PubMed Central ID: PMC8103304]. <https://doi.org/10.2196/25759>.
63. Shapiro MA, Stuhlmiller TJ, Wasserman A, Kramer GA, Federowicz B, Hoos W, et al. AI-Augmented Clinical Decision Support in a Patient-Centric Precision Oncology Registry. *AI Precision Oncol*. 2024;1(1):58-68. <https://doi.org/10.1089/aipo.2023.0001>.
64. Chavda V, Anand K, Apostolopoulos V. *Bioinformatics Tools for Pharmaceutical Drug Product Development*. Hoboken, New Jersey: WILEY; 2023. <https://doi.org/10.1002/9781119865728>.
65. Hasanzadeh A, Hamblin MR, Kiani J, Noori H, Hardie JM, Karimi M, et al. Could artificial intelligence revolutionize the development of nanovectors for gene therapy and mRNA vaccines? *Nano Today*. 2022;47. [PubMed ID: 37034382]. [PubMed Central ID: PMC10081506]. <https://doi.org/10.1016/j.nantod.2022.101665>.
66. Kim J, McFee M, Fang Q, Abdin O, Kim PM. Computational and artificial intelligence-based methods for antibody development. *Trends Pharmacol Sci*. 2023;44(3):175-89. [PubMed ID: 36669976]. <https://doi.org/10.1016/j.tips.2022.12.005>.
67. Mottaghi-Dastjerdi N, Ghorbani A, Montazeri H, Guzzi PH. A systems biology approach to pathogenesis of gastric cancer: gene network modeling and pathway analysis. *BMC Gastroenterol*. 2023;23(1):248. <https://doi.org/10.1186/s12876-023-02891-4>.
68. Gomes P, Gomes DEB, Bernardi RC. Protein structure prediction in the era of AI: Challenges and limitations when applying to in silico force spectroscopy. *Front Bioinform*. 2022;2:983306. [PubMed ID: 36304287]. [PubMed Central ID: PMC9580946]. <https://doi.org/10.3389/fbinf.2022.983306>.
69. Alrefaei AF, Hawsawi YM, Almaleki D, Alarif T, Alzahrani FA, Bakhrebah MA. Genetic data sharing and artificial intelligence in the era of personalized medicine based on a cross-sectional analysis of the Saudi human genome program. *Sci Rep*. 2022;12(1):1405. [PubMed ID: 35082362]. [PubMed Central ID: PMC8791994]. <https://doi.org/10.1038/s41598-022-05296-7>.
70. Helleckes LM, Hemmerich J, Wiechert W, von Lieres E, Grünberger A. Machine learning in bioprocess development: from promise to practice. *Trends Biotechnol*. 2023;41(6):817-35. [PubMed ID: 36456404]. <https://doi.org/10.1016/j.tibtech.2022.10.010>.
71. DiNuzzo M. How artificial intelligence enables modeling and simulation of biological networks to accelerate drug discovery. *Frontiers in Drug Discovery*. 2022;2. <https://doi.org/10.3389/fddsv.2022.1019706>.

72. Vazquez-Levin MH, Reventos J, Zaki G. Editorial: Artificial intelligence: A step forward in biomarker discovery and integration towards improved cancer diagnosis and treatment. *Frontiers Oncol.* 2023;**13**. <https://doi.org/10.3389/fonc.2023.116118>.
73. Yang F, Zhang Q, Ji X, Zhang Y, Li W, Peng S, et al. Machine Learning Applications in Drug Repurposing. *Interdiscip Sci.* 2022;**14**(1):15-21. [PubMed ID: 35066811]. [PubMed Central ID: PMC8783773]. <https://doi.org/10.1007/s12539-021-00487-8>.
74. BioProcess International. *Artificial Intelligence in the Biopharmaceutical Industry: Treacherous or Transformative?*. 2024. Available from: <https://www.bioprocessintl.com/information-technology/artificial-intelligence-in-the-biopharmaceutical-industry-treacherous-or-transformative->.
75. Saberi-Movahed F, Mohammadifard M, Mehrpooya A, Rezaei-Ravari M, Berahmand K, Rostami M, et al. Decoding Clinical Biomarker Space of COVID-19: Exploring Matrix Factorization-based Feature Selection Methods. *medRxiv.* 2021. [PubMed ID: 34268522]. [PubMed Central ID: PMC8282111]. <https://doi.org/10.1101/2021.07.07.21259699>.
76. Tanoli Z, Vähä-Koskela M, Aittokallio T. Artificial intelligence, machine learning, and drug repurposing in cancer. *Expert Opin Drug Discov.* 2021;**16**(9):977-89. [PubMed ID: 33543671]. <https://doi.org/10.1080/17460441.2021.1883585>.
77. Alshawwa SZ, Kassem AA, Farid RM, Mostafa SK, Labib GS. Nanocarrier Drug Delivery Systems: Characterization, Limitations, Future Perspectives and Implementation of Artificial Intelligence. *Pharmaceutics.* 2022;**14**(4). [PubMed ID: 35456717]. [PubMed Central ID: PMC9026217]. <https://doi.org/10.3390/pharmaceutics14040883>.
78. Tome I, Francisco V, Fernandes H, Ferreira L. High-throughput screening of nanoparticles in drug delivery. *APL Bioeng.* 2021;**5**(3):31511. [PubMed ID: 34476328]. [PubMed Central ID: PMC8397474]. <https://doi.org/10.1063/5.0057204>.
79. Singh AV, Varma M, Laux P, Choudhary S, Datusalia AK, Gupta N, et al. Artificial intelligence and machine learning disciplines with the potential to improve the nanotoxicology and nanomedicine fields: a comprehensive review. *Arch Toxicol.* 2023;**97**(4):963-79. [PubMed ID: 36878992]. [PubMed Central ID: PMC10025217]. <https://doi.org/10.1007/s00204-023-03471-x>.
80. Jamshidi MB, Lalbakhsh A, Talla J, Peroutka Z, Hadjilooei F, Lalbakhsh P, et al. Artificial Intelligence and COVID-19: Deep Learning Approaches for Diagnosis and Treatment. *IEEE Access.* 2020;**8**:109581-95. [PubMed ID: 34192103]. [PubMed Central ID: PMC8043506]. <https://doi.org/10.1109/ACCESS.2020.3001973>.
81. Yadav SK, Yadav RD, Tabassum H, Arya M. Recent Developments in Nanotechnology-Based Biosensors for the Diagnosis of Coronavirus. *Plasmonics.* 2023;**18**(3):955-69. [PubMed ID: 37229148]. [PubMed Central ID: PMC10040920]. <https://doi.org/10.1007/s11468-023-01822-z>.
82. Svensson E, von Mentzer U, Stubelius A. Achieving Precision Healthcare through Nanomedicine and Enhanced Model Systems. *ACS Materials Au.* 2024;**4**(2):162-73. <https://doi.org/10.1021/acsmaterialsau.3c00073>.
83. Jiang Y, Salley D, Sharma A, Keenan G, Mullin M, Cronin L. An artificial intelligence enabled chemical synthesis robot for exploration and optimization of nanomaterials. *Sci Adv.* 2022;**8**(40):eabo2626. [PubMed ID: 36206340]. [PubMed Central ID: PMC9544322]. <https://doi.org/10.1126/sciadv.abo2626>.
84. AstraZenca IMED Biotech Unit. *Delivering the next wave of scientific innovation.* 2017. Available from: https://www.astrazeneca.com/content/dam/az/PDF/2017/IMED_Annual%20Review%202017_FINAL%20APPROVED.pdf.
85. CARDIFF Uuniversity. *AI-generated nanoparticles prove capable of delivering modern medicines to diseased cells.* 2023. Available from: <https://www.cardiff.ac.uk/news/view/2728830-ai-generated-nanoparticles-prove-capable-of-delivering-modern-medicines-to-diseased-cells>.
86. Banaye Yazdipour A, Masoorian H, Ahmadi M, Mohammadzadeh N, Ayyoubzadeh SM. Predicting the toxicity of nanoparticles using artificial intelligence tools: a systematic review. *Nanotoxicol.* 2023;**17**(1):62-77. [PubMed ID: 36883698]. <https://doi.org/10.1080/17435390.2023.2186279>.
87. Mullowney MW, Duncan KR, Elsayed SS, Garg N, van der Hooft JJJ, Martin NI, et al. Artificial intelligence for natural product drug discovery. *Nat Rev Drug Discov.* 2023;**22**(11):895-916. [PubMed ID: 37697042]. <https://doi.org/10.1038/s41573-023-00774-7>.
88. Cortés I, Cuadrado C, Hernández Daranas A, Sarotti AM. Machine learning in computational NMR-aided structural elucidation. *Frontiers in Natural Products.* 2023;**2**. <https://doi.org/10.3389/fntpr.2023.1122426>.
89. Böhlen M, Sujarwo W. Machine Learning in Ethnobotany. *Indonesian Institute of Sciences.* 2020;**Preprint**. <https://doi.org/10.1109/SMC42975.2020.9283069>.
90. Ayon NJ. High-Throughput Screening of Natural Product and Synthetic Molecule Libraries for Antibacterial Drug Discovery. *Metabolites.* 2023;**13**(5). [PubMed ID: 37233666]. [PubMed Central ID: PMC10220967]. <https://doi.org/10.3390/metabo13050625>.
91. Wang T, Wang XW, Lee-Sarwar KA, Litonjua AA, Weiss ST, Sun Y, et al. Predicting metabolomic profiles from microbial composition through neural ordinary differential equations. *Nat Mach Intell.* 2023;**5**(3):284-93. [PubMed ID: 38223254]. [PubMed Central ID: PMC10786629]. <https://doi.org/10.1038/s42256-023-00627-3>.
92. Zhou E, Shen Q, Hou Y. Integrating artificial intelligence into the modernization of traditional Chinese medicine industry: a review. *Front Pharmacol.* 2024;**15**:1181183. [PubMed ID: 38464717]. [PubMed Central ID: PMC10921893]. <https://doi.org/10.3389/fphar.2024.1181183>.
93. Chu H, Moon S, Park J, Bak S, Ko Y, Youn BY. The Use of Artificial Intelligence in Complementary and Alternative Medicine: A Systematic Scoping Review. *Front Pharmacol.* 2022;**13**:826044. [PubMed ID: 35431917]. [PubMed Central ID: PMC901141]. <https://doi.org/10.3389/fphar.2022.826044>.
94. Silvestro D, Gorla S, Sterner T, Antonelli A. Improving biodiversity protection through artificial intelligence. *Nat Sustain.* 2022;**5**(5):415-24. [PubMed ID: 35614933]. [PubMed Central ID: PMC7612764]. <https://doi.org/10.1038/s41893-022-00851-6>.
95. Desai N, Patel D, Vyas N. Pharmacognosy with Artificial Intelligence: An Interdisciplinary Approach. In: Tiwari S, Trivedi MC, Kolhe ML, Mishra KK, Singh BK, editors. *Advances in Data and Information Sciences.* 2022//; Singapore. Springer Singapore; 2022. p. 167-77.
96. Gallicchio E, Ferdous N, Reza MN, Hossain MU, Mahmud S, Napis S, et al. Mpropred: A machine learning (ML) driven Web-App for bioactivity prediction of SARS-CoV-2 main protease (Mpro) antagonists. *Plos One.* 2023;**18**(6). <https://doi.org/10.1371/journal.pone.0287179>.
97. Walter S. AI impacts on supply chain performance : a manufacturing use case study. *Discover Artificial Intelligence.* 2023;**3**(1):18. <https://doi.org/10.1007/s44163-023-00061-9>.
98. Klaus B. AI Models and Drug Discovery Within Pharmaceutical Drug Market. *Dela J Public Health.* 2023;**9**(4):52-3. [PubMed ID: 38173958]. [PubMed Central ID: PMC10759970]. <https://doi.org/10.32481/djph.2023.11.009>.
99. Padula WV, Kreif N, Vanness DJ, Adamson B, Rueda JD, Felizzi F, et al. Machine Learning Methods in Health Economics and Outcomes Research-The PALISADE Checklist: A Good Practices Report of an ISPOR Task Force. *Value Health.* 2022;**25**(7):1063-80. [PubMed ID: 35779937]. <https://doi.org/10.1016/j.jval.2022.03.022>.
100. Vora LK, Gholap AD, Jetha K, Thakur RRS, Solanki HK, Chavda VP. Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design. *Pharmaceutics.* 2023;**15**(7). [PubMed ID: 37514102].

- [PubMed Central ID: PMC10385763]. <https://doi.org/10.3390/pharmaceutics15071916>.
101. Kumar A, Mani V, Jain V, Gupta H, Venkatesh VG. Managing healthcare supply chain through artificial intelligence (AI): A study of critical success factors. *Comput Ind Eng*. 2023;**175**:108815. [PubMed ID: 36405396]. [PubMed Central ID: PMC9664836]. <https://doi.org/10.1016/j.cie.2022.108815>.
 102. Vyas DA, Eisenstein LG, Jones DS. Hidden in Plain Sight - Reconsidering the Use of Race Correction in Clinical Algorithms. *N Engl J Med*. 2020;**383**(9):874-82. [PubMed ID: 32853499]. <https://doi.org/10.1056/NEJMms2004740>.
 103. Zahoor K, Bawany NZ, Ghani U. Explainable AI for Healthcare: An Approach Towards Interpretable Healthcare Models. *2023 24th International Arab Conference on Information Technology (ACIT)*. 2023. p. 1-7.
 104. Ranjan A, Singh D. The Inevitability Prospects of Regulatory Information Management Software RegDesk to Ease Regulation Approvals. *Rev Recent Clin Trials*. 2024;**19**(1):4-6. [PubMed ID: 37817513]. <https://doi.org/10.2174/0115748871254734230929201816>.
 105. Ajalkar DA, Sharma YK, Shinde JP, Nayak S. Ethical and Legal Considerations in Machine Learning. In: Lilhore UK, Kumar A, Simaiya S, Vyas N, Dutt V, editors. *Applying Machine Learning Techniques to Bioinformatics*. Hershey, Pennsylvania: IGI Global; 2024. p. 62-74. <https://doi.org/10.4018/979-8-3693-1822-5.ch004>.
 106. Vasconcelos H, Jörke M, Grunde-McLaughlin M, Gerstenberg T, Bernstein MS, Krishna R. Explanations Can Reduce Overreliance on AI Systems During Decision-Making. *Proceedings ACM Human-Computer Interact*. 2023;**7**(CSCW1):1-38. <https://doi.org/10.1145/3579605>.
 107. Groper E. Artificial Intelligence and Intellectual Property: AI-Driven Drug Discovery and the Challenges It Poses to the Canadian Patent System. *Can L Libr Rev*. 2023;**48**:9.
 108. Balagurunathan Y, Mitchell R, El Naqa I. Requirements and reliability of AI in the medical context. *Phys Med*. 2021;**83**:72-8. [PubMed ID: 33721700]. [PubMed Central ID: PMC8915137]. <https://doi.org/10.1016/j.ejmp.2021.02.024>.
 109. Khanna NN, Maindarkar MA, Viswanathan V, Fernandes JFE, Paul S, Bhagawati M, et al. Economics of Artificial Intelligence in Healthcare: Diagnosis vs. Treatment. *Healthcare (Basel)*. 2022;**10**(12). [PubMed ID: 36554017]. [PubMed Central ID: PMC9777836]. <https://doi.org/10.3390/healthcare10122493>.
 110. Schneider G. Automating drug discovery. *Nat Rev Drug Discov*. 2018;**17**(2):97-113. [PubMed ID: 29242609]. <https://doi.org/10.1038/nrd.2017.232>.
 111. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. *Nat Med*. 2019;**25**(1):44-56. [PubMed ID: 30617339]. <https://doi.org/10.1038/s41591-018-0300-7>.
 112. Esteva A, Robicquet A, Ramsundar B, Kuleshov V, DePristo M, Chou K, et al. A guide to deep learning in healthcare. *Nat Med*. 2019;**25**(1):24-9. [PubMed ID: 30617335]. <https://doi.org/10.1038/s41591-018-0316-z>.
 113. Cazzaniga M, Jaumotte MF, Li L, Melina MG, Panton AJ, Pizzinelli C, et al. *Gen-AI: Artificial intelligence and the future of work*. Washington: International Monetary Fund; 2024.
 114. Mittelstadt BD, Allo P, Taddeo M, Wachter S, Floridi L. The ethics of algorithms: Mapping the debate. *Big Data Soc*. 2016;**3**(2):2053951716679680.
 115. Davenport T, Kalakota R. The potential for artificial intelligence in healthcare. *Future Healthc J*. 2019;**6**(2):94-8. [PubMed ID: 31363513]. [PubMed Central ID: PMC6616181]. <https://doi.org/10.7861/futurehosp.6-2-94>.